Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has provided an update.
JW (Cayman) Therapeutics Co. Ltd. has announced the grant of 4,204,490 share options to Mr. Min Liu, the company’s chairman and CEO, under its Post-IPO Incentivization Scheme. This grant is subject to shareholder approval as it exceeds 1% of the company’s issued shares, highlighting the company’s commitment to aligning leadership incentives with shareholder interests.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company focused on developing, manufacturing, and commercializing cell-based immunotherapies for cancer treatment. The company operates within the healthcare industry, with a specific emphasis on innovative therapies targeting hematological malignancies and solid tumors.
Average Trading Volume: 5,203,895
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.16B
See more insights into 2126 stock on TipRanks’ Stock Analysis page.